	US 12,319,726 B2
	Method for treating CD40-mediated diseases
Carlos Subauste, Cleveland, OH (US); and Cecilia Subauste, Cleveland, OH (US)
Assigned to CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed by CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US); and Carlos Subauste, Cleveland, OH (US)
Filed on Jun. 2, 2020, as Appl. No. 16/890,486.
Application 16/890,486 is a continuation in part of application No. 15/346,252, filed on Nov. 8, 2016, granted, now 10,669,345.
Application 15/346,252 is a continuation in part of application No. 12/993,375, granted, now 9,486,498, issued on Nov. 8, 2016, previously published as PCT/US2009/044500, filed on May 19, 2009.
Claims priority of provisional application 63/004,026, filed on Apr. 2, 2020.
Claims priority of provisional application 61/054,293, filed on May 19, 2008.
Prior Publication US 2020/0308252 A1, Oct. 1, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/435 (2006.01); A61P 29/00 (2006.01); C07K 14/705 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/70578 (2013.01) [A61P 29/00 (2018.01); A61K 38/00 (2013.01)]

6 Claims

1. A composition comprising:

a cell-permeable polypeptide that competitively inhibits binding of TRAF2 to the TRAF2,3 binding domain of CD40 of cells, the cell-permeable polypeptide comprising a membrane transduction domain and a retro-inverso peptide of a CD40-TRAF2,3 blocking peptide comprising the amino acid sequence that is at least 70% identical to SEQ ID NO: 10.